HS 10345
Alternative Names: HS-10345Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for phase-I development in Depressive disorders(Treatment-resistant, In adults) in China (Intranasal, Spray)
- 31 Oct 2022 Jiangsu Hansoh Pharmaceutical completes a phase I clinical trial in Depressive disorders (Treatment-resistant, In adults) in China (Intranasal) (NCT05196971)
- 28 Oct 2021 Phase-I clinical trials in Depressive disorders (Treatment-resistant, In adults) in China (Intranasal) (NCT05196971)